Smarter Wound Care Starts Here
EnzyLock is a bacteria-responsive smart hydrogel that detects and treats wound infection in real time, without adding clinical complexity.
Discover EnzyLock
The Problem is Larger Than You Think
Chronic wound infections affect millions of patients annually across multiple care settings, driving avoidable complications, rising costs, and preventable amputations.
~$0B
Global Chronic Wound Treatment Market
Growing at 6% CAGR annually
0.0M
Americans Affected by Diabetic Foot Ulcers
The leading driver of non-traumatic lower-limb amputation
Up to 0%
Infection Rate in High-Risk Wounds
With 70% resistant to at least one antibiotic
0-72hrs
Current Culture Result Turnaround
Leaving infections undetected and untreated for days
~$0K
Per-Patient Treatment Cost
Driven by repeated interventions, hospitalizations, and surgical procedures
0%
Amputations Preceded by Infection
Early detection and treatment could prevent the majority of lower-limb loss
Sources available upon request.
The Problem
Chronic wound infections affect millions of patients annually. Delayed detection, antibiotic resistance, and inadequate dressings drive avoidable complications, amputations, and enormous healthcare costs.
Our Vision
At Red Maple LifeSciences, we are developing smart biomaterial solutions that respond to the biology of infection, giving clinicians earlier insight and more targeted treatment at the point of care.
EnzyLock Smart Hydrogel Platform
The platform integrates two core functions: real-time bacterial detection through visible color change, and precision antimicrobial delivery triggered only by bacterial presence.
EnzyLock is designed to improve infection response while fitting into existing wound care workflows.
Learn More
Backed by World-Class Institutions
“EnzyLock represents a fundamentally new approach to wound care, one that responds to the biology of the wound itself.”
Red Maple LifeSciences Advisory Board